Ace Therapeutics offers a comprehensive in vivo Liver Injury model development service, designed to accelerate the discovery and evaluation of novel therapeutics for liver diseases. Leveraging a diverse portfolio of validated animal models, our platform supports preclinical research with robust, reproducible, and translationally relevant solutions tailored to your scientific objectives.
The study of liver injury and its underlying mechanisms requires animal models that faithfully recapitulate the complexity of human liver diseases. At Ace Therapeutics, we utilize a wide range of species and strains, including zebrafish (Danio rerio), mice (Mus musculus; strains such as Balb/c, C57BL/6, Kunming, NOD, NSG, FRG, CD-1), and rats (Rattus norvegicus; Sprague Dawley, Wistar). These models enable the investigation of diverse etiologies of liver injury—chemical, biological, dietary, genetic, and surgical—mirroring the multifactorial nature of human hepatic pathology. Our models provide essential platforms for elucidating disease mechanisms, identifying therapeutic targets, and evaluating the efficacy and safety of candidate compounds.
Chemically-induced liver injury models involve the administration of hepatotoxic agents such as paracetamol (acetaminophen), D-galactosamine, perchloromethane, ethanol, thioacetamide, and others to induce acute or chronic liver damage. The methodology typically includes a single or repeated dosing regimen, tailored to mimic specific types of liver injury (e.g., hepatocellular necrosis, steatosis, fibrosis). Key advantages include high reproducibility, dose-dependent injury, and well-characterized pathophysiology relevant to human toxicant-induced liver diseases. These models are widely used for mechanistic studies, drug efficacy screening, biomarker discovery, and hepatoprotective agent evaluation.
Biologically-induced models use agents such as lipopolysaccharide (LPS), concanavalin A, or tumor necrosis factor alpha (TNF-α) to trigger immune-mediated liver injury. Administration is typically via intravenous or intraperitoneal injection, leading to inflammation, immune cell infiltration, and hepatocyte apoptosis or necrosis. These models are particularly valuable for studying immune responses, cytokine-mediated hepatotoxicity, and the interplay between inflammation and liver pathology. They are instrumental in evaluating immunomodulatory therapies and dissecting the molecular drivers of autoimmune or infectious liver injury.
Dietary and metabolic models simulate liver injury through nutritional manipulation, such as high-fat diets, DDC-supplemented diets, or ethanol feeding. These approaches induce steatosis, steatohepatitis, and metabolic dysfunction, closely resembling non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), and cholestatic injury in humans. The methodology involves controlled feeding protocols over several weeks. Advantages include the ability to model chronic, progressive liver injury and to study interactions between diet, metabolism, and hepatic pathology. These models are crucial for investigating the pathogenesis of metabolic liver diseases and for testing lifestyle and pharmacological interventions.
Genetic and transgenic liver injury models employ knockout, transgenic, or immunodeficient animals (e.g., Gsdme KO, Afp KO, INHBA transgenic, SCID, xenograft models) to study the genetic basis of liver disease or to humanize the hepatic environment. These models are generated via targeted gene editing or transplantation of human hepatocytes. They offer insights into gene function, disease susceptibility, and host-pathogen interactions, and are invaluable for evaluating gene therapies, cell-based interventions, and personalized medicine approaches.
Surgical models of liver injury, such as partial hepatectomy or associating liver partition and portal vein ligation, provide unique opportunities to study liver regeneration, ischemia/reperfusion injury, and post-surgical recovery. These models involve precise surgical procedures under anesthesia, with subsequent monitoring of liver function and regenerative capacity. They are ideal for assessing regenerative therapies, surgical techniques, and mechanisms of tissue repair.
Ace Therapeutics delivers a complete solution for in vivo liver injury model development, encompassing model selection, study design, execution, and comprehensive data analysis. Our service includes induction of liver injury using validated protocols, administration of test compounds, and rigorous monitoring throughout the study. Key efficacy endpoints and measurements include serum liver enzyme levels (ALT, AST, ALP), histopathological assessment (H&E, Masson's trichrome staining), liver weight and morphology, inflammatory and fibrotic marker quantification (qPCR, ELISA, immunohistochemistry), and survival analysis. Our analytical capabilities cover advanced imaging, flow cytometry, transcriptomics, proteomics, and metabolomics to provide a multidimensional view of liver injury and therapeutic response. Quality control is ensured through standardized operating procedures, experienced technical staff, and adherence to ethical and regulatory guidelines, guaranteeing reproducibility and scientific validity.
By partnering with Ace Therapeutics, you gain access to a versatile, scientifically validated platform for preclinical liver injury research. Our expert team collaborates closely with clients to customize studies, accelerate timelines, and generate high-impact data to support your therapeutic development. Discover the difference that comprehensive, reliable, and translationally relevant in vivo liver injury models can make—contact Ace Therapeutics today to discuss your project needs.
| Species | Strain | Characteristic (Details) |
|---|---|---|
| Danio rerio (zebrafish) | Chemical agent-induced (paracetamol) | |
| Mus musculus (mouse) | Balb/c | Biological agent-induced (concanavalin A) |
| Mus musculus (mouse) | Balb/c | Biological agent-induced (lipopolysaccharide); Chemical agent-induced (D-galactosamine) |
| Mus musculus (mouse) | Balb/c | Chemical agent-induced (concanavalin A) |
| Mus musculus (mouse) | Balb/c | Chemical agent-induced (olive oil); Chemical agent-induced (perchloromethane) |
| Mus musculus (mouse) | Balb/c | Chemical agent-induced (paracetamol) |
| Mus musculus (mouse) | Balb/c | Chemical agent-induced (paracetamol) |
| Mus musculus (mouse) | Balb/c | Chemical agent-induced (paracetamol); Fasted |
| Mus musculus (mouse) | Balb/c | Chemical agent-induced (paracetamol); Nude |
| Mus musculus (mouse) | Balb/c | Chemical agent-induced (perchloromethane) |
| Mus musculus (mouse) | Balb/c | Chemical agent-induced (perchloromethane) |
| Mus musculus (mouse) | Balb/c | Chemical agent-induced (perchloromethane); Knockout (Afp) |
| Mus musculus (mouse) | Balb/c | Chemical agent-induced (toosendanin) |
| Mus musculus (mouse) | Balb/cByJNarl | Chemical agent-induced (propacetamol hydrochloride); Fasted |
| Mus musculus (mouse) | C57 | Chemical agent-induced (concanavalin A) |
| Mus musculus (mouse) | C57 | Chemical agent-induced (perchloromethane) |
| Mus musculus (mouse) | C57 | Chemical agent-induced (perchloromethane); Chemical agent-induced (thioacetamide) |
| Mus musculus (mouse) | C57/BL | Chemical agent-induced (paracetamol); Fasted |
| Mus musculus (mouse) | C57BL/6 | Biological agent-induced (lipopolysaccharide) |
| Mus musculus (mouse) | C57BL/6 | Biological agent-induced (lipopolysaccharide); Chemical agent-induced (D-galactosamine) |
| Mus musculus (mouse) | C57BL/6 | Biological agent-induced (lipopolysaccharide); Chemical agent-induced (N-galactosamine) |
| Mus musculus (mouse) | C57BL/6 | Chemical agent-induced (concanavalin A) |
| Mus musculus (mouse) | C57BL/6 | Chemical agent-induced (concanavalin A) |
| Mus musculus (mouse) | C57BL/6 | Chemical agent-induced (ethanol); High-fat diet |
| Mus musculus (mouse) | C57BL/6 | Chemical agent-induced (paracetamol) |
| Mus musculus (mouse) | C57BL/6 | Chemical agent-induced (paracetamol) |
| Mus musculus (mouse) | C57BL/6 | Chemical agent-induced (paracetamol); Fasted |
| Mus musculus (mouse) | C57BL/6 | Chemical agent-induced (paracetamol); Fasted |
| Mus musculus (mouse) | C57BL/6 | Chemical agent-induced (perchloromethane) |
| Mus musculus (mouse) | C57BL/6 | Chemical agent-induced (perchloromethane) |
| Mus musculus (mouse) | C57BL/6 | Chemical agent-induced (perchloromethane); Fasted; High-fat diet |
| Mus musculus (mouse) | C57BL/6 | Chemical agent-induced (thioacetamide) |
| Mus musculus (mouse) | C57BL/6 | DDC-supplemented diet-induced |
| Mus musculus (mouse) | C57BL/6J | Biological agent-induced (lipopolysaccharide); Chemical agent-induced (D-galactosamine) |
| Mus musculus (mouse) | C57BL/6J | Biological agent-induced (tumor necrosis factor alpha); Chemical agent-induced (D-galactosamine) |
| Mus musculus (mouse) | C57BL/6J | Chemical agent-induced (concanavalin A) |
| Mus musculus (mouse) | C57BL/6J | Chemical agent-induced (paracetamol) |
| Mus musculus (mouse) | C57BL/6J | Chemical agent-induced (paracetamol) |
| Mus musculus (mouse) | C57BL/6J | Chemical agent-induced (paracetamol); Fasted |
| Mus musculus (mouse) | C57BL/6J | Chemical agent-induced (paracetamol); Fasted |
| Mus musculus (mouse) | C57BL/6J | Chemical agent-induced (paracetamol); Knockout (Gsdme) |
| Mus musculus (mouse) | C57BL/6J | Chemical agent-induced (perchloromethane) |
| Mus musculus (mouse) | C57BL/6J | Partial hepatectomy |
| Mus musculus (mouse) | C57BL/6JRj | Chemical agent-induced (paracetamol) |
| Mus musculus (mouse) | C57BL/6N | Chemical agent-induced (ethanol) |
| Mus musculus (mouse) | C57BL/6N | Chemical agent-induced (paracetamol); Fasted |
| Mus musculus (mouse) | CD-1 | Biological agent-induced (lipopolysaccharide) |
| Mus musculus (mouse) | FRG | Chemical agent-induced (paracetamol); Fasted; Immunosuppressed |
| Mus musculus (mouse) | Kunming | Biological agent-induced (lipopolysaccharide); Chemical agent-induced (D-galactosamine) |
| Mus musculus (mouse) | Kunming | Chemical agent-induced (D-galactosamine) |
| Mus musculus (mouse) | Kunming | Chemical agent-induced (alpha-naphthylisothiocyanate) |
| Mus musculus (mouse) | Kunming | Chemical agent-induced (arsenite) |
| Mus musculus (mouse) | Kunming | Chemical agent-induced (paracetamol) |
| Mus musculus (mouse) | Kunming | Chemical agent-induced (perchloromethane) |
| Mus musculus (mouse) | Kunming | Chemical agent-induced (simvastatin) |
| Mus musculus (mouse) | Kunming | Chemical agent-induced (thioacetamide) |
| Mus musculus (mouse) | NOD | Biological agent-induced (lipopolysaccharide); Chemical agent-induced (D-galactosamine); Severe combined immune deficiency (SCID) |
| Mus musculus (mouse) | NOD | Chemical agent-induced (ethanol); Severe combined immune deficiency (SCID) |
| Mus musculus (mouse) | NSG | Chemical agent-induced (paracetamol); Xenograft (Hepatocytes (primary), human) |
| Mus musculus (mouse) | NSG | Chemical agent-induced (perchloromethane) |
| Mus musculus (mouse) | Associating liver partition and portal vein ligation for staged hepatectomy | |
| Mus musculus (mouse) | Biological agent-induced (lipopolysaccharide); Chemical agent-induced (D-galactosamine) | |
| Mus musculus (mouse) | Chemical agent-induced (3,5-diethoxycarbony1-1,4-dihydrocollidine) | |
| Mus musculus (mouse) | Chemical agent-induced (D-galactosamine) | |
| Mus musculus (mouse) | Chemical agent-induced (D-galactosamine) | |
| Mus musculus (mouse) | Chemical agent-induced (N-galactosamine) | |
| Mus musculus (mouse) | Chemical agent-induced (ethanol) | |
| Mus musculus (mouse) | Chemical agent-induced (ethanol) | |
| Mus musculus (mouse) | Chemical agent-induced (ethanol) | |
| Mus musculus (mouse) | Chemical agent-induced (oxaliplatin) | |
| Mus musculus (mouse) | Chemical agent-induced (paracetamol) | |
| Mus musculus (mouse) | Chemical agent-induced (paracetamol) | |
| Mus musculus (mouse) | Chemical agent-induced (paracetamol); Knockout (Nr2e3) | |
| Mus musculus (mouse) | Chemical agent-induced (paracetamol); Knockout (Optn) | |
| Mus musculus (mouse) | Chemical agent-induced (paracetamol); Knockout (Panx1) | |
| Mus musculus (mouse) | Chemical agent-induced (perchloromethane) | |
| Mus musculus (mouse) | Chemical agent-induced (perchloromethane) | |
| Mus musculus (mouse) | Chemical agent-induced (perchloromethane); Fasted | |
| Mus musculus (mouse) | Chemical agent-induced (perchloromethane); Knockout (Nr2e3) | |
| Mus musculus (mouse) | Chemical agent-induced (perchloromethane); Severe combined immune deficiency (SCID) | |
| Mus musculus (mouse) | Chemical agent-induced (sulfur mustard) | |
| Mus musculus (mouse) | Transgenic (INHBA) | |
| Rattus norvegicus (rat) | Sprague Dawley | Chemical agent-induced ((+)-galactose) |
| Rattus norvegicus (rat) | Sprague Dawley | Chemical agent-induced ((+)-genipin) |
| Rattus norvegicus (rat) | Sprague Dawley | Chemical agent-induced (4,4-methylinedianiline) |
| Rattus norvegicus (rat) | Sprague Dawley | Chemical agent-induced (D-galactosamine) |
| Rattus norvegicus (rat) | Sprague Dawley | Chemical agent-induced (paracetamol) |
| Rattus norvegicus (rat) | Sprague Dawley | Chemical agent-induced (perchloromethane) |
| Rattus norvegicus (rat) | Sprague Dawley | Partial hepatectomy |
| Rattus norvegicus (rat) | Wistar | Chemical agent-induced (ethanol) |
| Rattus norvegicus (rat) | Wistar albino | Ischemia/reperfusion |
Make Order
Experimental Scheme
Implementation
Conclusion